Traws Pharma Inc. (TRAW) Shares Plummet Below 1-Year High

Traws Pharma Inc. (NASDAQ: TRAW)’s stock price has plunge by -13.07relation to previous closing price of 1.00. Nevertheless, the company has seen a -3.87% plunge in its stock price over the last five trading sessions.

Is It Worth Investing in Traws Pharma Inc. (NASDAQ: TRAW) Right Now?

The 36-month beta value for TRAW is at 1.35.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for TRAW is 20.84M, and currently, shorts hold a 0.10% of that float. The average trading volume for TRAW on April 03, 2024 was 96.38K shares.

TRAW’s Market Performance

The stock of Traws Pharma Inc. (TRAW) has seen a -3.87% decrease in the past week, with a -6.97% drop in the past month, and a 9.52% gain in the past quarter. The volatility ratio for the week is 12.39%, and the volatility levels for the past 30 days are at 9.49% for TRAW. The simple moving average for the last 20 days is -4.94% for TRAW stock, with a simple moving average of 6.95% for the last 200 days.

Analysts’ Opinion of TRAW

Many brokerage firms have already submitted their reports for TRAW stocks, with Ladenburg Thalmann repeating the rating for TRAW by listing it as a “Buy.” The predicted price for TRAW in the upcoming period, according to Ladenburg Thalmann is $7 based on the research report published on March 01, 2022 of the previous year 2022.

Guggenheim, on the other hand, stated in their research note that they expect to see TRAW reach a price target of $4. The rating they have provided for TRAW stocks is “Buy” according to the report published on May 18th, 2021.

H.C. Wainwright gave a rating of “Buy” to TRAW, setting the target price at $7.50 in the report published on March 01st of the previous year.

TRAW Trading at 9.06% from the 50-Day Moving Average

After a stumble in the market that brought TRAW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.33% of loss for the given period.

Volatility was left at 9.49%, however, over the last 30 days, the volatility rate increased by 12.39%.

In addition, Traws Pharma Inc. saw 16.04% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for TRAW

Equity return is now at value -97.22, with -61.07 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 2.46.


In conclusion, Traws Pharma Inc. (TRAW) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts